AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21927856
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (200 ml h(‐1) of a mixture of 18 amino acids)
Trial: 21927856
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (200 ml h(‐1))
Trial: 21927856
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion and saline infusion
Trial: 7970548
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol and atropine combined
Trial: 3310418
Drug: Hyaluronidase (H.)
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase (H.) in combination with systemic or intravesical chemotherapy
Trial: 28135023
Drug: NSAIDs and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs and/or paracetamol
Trial: 28135023
Drug: Both NSAIDs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both NSAIDs and paracetamol
Trial: 26249767
Drug: LEVO 200
RxNorm normalized name: Stalevo 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEVO 200 µg once-daily
Trial: 26249767
Drug: LEVO 200
RxNorm normalized name: Stalevo 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEVO 200 µg twice-daily
Trial: 26249767
Drug: LEVO 200
RxNorm normalized name: Stalevo 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEVO 200 µg once-daily vs LEVO 200 µg twice-daily
Trial: 19857150
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy with low-molecular-weight heparins
Trial: 19857150
Drug: VTE prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTE prophylaxis and/or prompt treatment
Trial: 15272643
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg/day (group A)
Trial: 9549924
Drug: CMV‐IgG 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV‐IgG 100 mg/kg/week
Trial: 9549924
Drug: HDIgG 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDIgG 400 mg/kg/week
Trial: 8172750
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (pre-existing condition)
Trial: 2830688
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant interferon-alpha-2C (rIFNa2C)
Trial: 21849980
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial magnetic stimulation (TMS) at 10 Hz, specific details on dosage and duration not available.
Trial: 12687650
Drug: MTHFR(C677T) genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTHFR(C677T) genotype CC
Trial: 12742280
Drug: Tezosentan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezosentan (25 mg/h for 1 h, then 50 mg/h for 23 to 47 h)
Trial: 1734558
Drug: Intermittent feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent feeding (1-hourly, 2-hourly, 3-hourly)
Trial: 6143868
Drug: 3 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus seven monthly HBIg injections
Trial: 6143868
Drug: 3 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus one HBIg injection at birth
Trial: 6143868
Drug: Only the
RxNorm normalized name: Product containing only theophylline (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only the vaccine at months 0, 1, 2, and 6
Trial: 6143868
Drug: Placebos for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos for both vaccine and HBIg
Trial: 3525266
Drug: Intensive conventional
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive conventional insulin therapy (ICT)
Trial: 29031905
Drug: Tesamorelin, 2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesamorelin, 2mg daily for six months
Trial: 19916292
Drug: Acupoint-catgut implantation
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint-catgut implantation (once every two weeks for the first 6 treatments, then once a month for 1 year)
Trial: 19916292
Drug: Massage (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage (20 mm, once daily for 1 year)
Trial: 16491584
Drug: 5% inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% inhaled CO2 during tilt
Trial: 15270743
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with lansoprazole plus amoxicillin and tinidazole
Trial: 15270743
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with amoxicillin and tinidazole
Trial: 8995552
Drug: 0.06 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/m2 rhTNF‐alpha intraperitoneally after drainage of fluid
Trial: 8353072
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, adriamycin 50 mg/m2, ifosfamide 5 G/m2) for 6 cycles at monthly intervals
Trial: 8353072
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose chemotherapy (cyclophosphamide 300 mg/m2, carboplatin 150 mg/m2, adriamycin 25 mg/m2, ifosfamide 2.5 G/m2) for 12 cycles at monthly intervals
Trial: 8353072
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose chemotherapy (300 mg/m2 cyclophosphamide and 150 mg/m2 carboplatin) for 12 cycles
Trial: 8353072
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose chemotherapy (600 mg/m2 cyclophosphamide and 300 mg/m2 carboplatin) for 6 cycles
Trial: 8353072
Drug: Both standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both standard and low dose cycles of chemotherapy
Trial: 3301453
Drug: Epomediol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epomediol (200 mg three times daily for 30 days)
Trial: 29104179
Drug: Six-month dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-month dual antiplatelet therapy (DAPT)
Trial: 23746564
Drug: Bicarbonate loading
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate loading (300 mg∙kg⁻¹)
Trial: 21344002
Drug: 2% PRO2000/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% PRO2000/5 microbicide gel
Trial: 18267977
Drug: Short intravenous
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short intravenous treatment (3 days of intravenous ceftriaxone followed by 5 days of oral antibiotics)
Trial: 18267977
Drug: Long intravenous
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long intravenous treatment (8 days of intravenous ceftriaxone)
Trial: 16584432
Drug: CAD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAD treatment
Trial: 11096148
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous epoetin beta (n=118)
Trial: 11096148
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or three times weekly subcutaneous epoetin beta (control group, n=40)
Trial: 11096148
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous epoetin beta
Trial: 11096148
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or three times weekly subcutaneous epoetin beta (control group)
Trial: 31460597
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion program (intervention group)
Trial: 29268886
Drug: Switched dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched dual antiplatelet therapy (DAPT)
Trial: 29268886
Drug: Unchanged dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unchanged dual antiplatelet therapy (DAPT)
Trial: 25844616
Drug: Topical epidermal
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical epidermal growth factor (EGF) serum applied twice daily for 12 weeks
Trial: 19003590
Drug: Selective photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective photodynamic therapy (PDT) using an optic fiber with an 810‐nm diode laser after indocyanine green (ICG) application
Trial: 15215810
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment combined with streptokinase
Trial: 10842419
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 400 mg of vitamin E and 500 mg of vitamin C
Trial: 9219199
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g.kg‐1)
Trial: 8378411
Drug: Maprotiline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (up to 75 mg/d)
Trial: 22471126
Drug: Auricular stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular stimulator in the cavum concha for 30 min, once daily for 3 months
Trial: 19834313
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g b.d, n=26)
Trial: 19834313
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (OCP) (35 g ethinyl estradiol/2 mg cyproterone acetate, n=30)
Trial: 18030228
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg and 40 mg once daily for 8 weeks
Trial: 15803017
Drug: Ondansetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.1 mg/kg)
Trial: 10195516
Drug: 0.1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL/kg 1% lidocaine i.v.
Trial: 10195516
Drug: 0.1 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL/kg isotonic sodium chloride solution (placebo control)
Trial: 6140939
Drug: Prizidilol hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prizidilol hydrochloride (400 mg)
Trial: 30702971
Drug: Celecoxib with
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib with neoadjuvant chemotherapy (NAC)
Trial: 24335026
Drug: Metformin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (250 mg 3 times a day for 7 days)
Trial: 22972538
Drug: Delayed-release doxylamine-pyridoxine
RxNorm normalized name: doxylamine / pyridoxine Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release doxylamine-pyridoxine (Diclectin)
Trial: 15460211
Drug: Ibuprofen lysine
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen lysine (IbuLys) 400 mg (two tablets of Dolormin as a single dose)
Trial: 15460211
Drug: Ibuprofen (Ibu)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (Ibu) 400 mg (two tablets as a single dose)
Trial: 11433224
Drug: VPA-985 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA-985 (50 or 100 mg twice daily)
Trial: 8179848
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 or 25 mg)
Trial: 8179848
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nebivolol and hydrochlorothiazide
Trial: 8179848
Drug: Nebivolol 10
RxNorm normalized name: nebivolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 10 mg combined with hydrochlorothiazide 25 mg
Trial: 3069520
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg choline theophyllinate administered orally every 12 h for 7 days
Trial: 3069520
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg anhydrous theophylline administered orally every 12 h for 7 days
Trial: 3069520
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg anhydrous theophylline
Trial: 3069520
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg choline theophyllinate
Trial: 25824436
Drug: Esophageal-directed hypnotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esophageal-directed hypnotherapy (EHYP) - 7 weekly sessions
Trial: 19889113
Drug: Pre-emptive fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 125 microg
Trial: 19889113
Drug: Pre-emptive fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 150 microg
Trial: 19889113
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% (0.5 ml) 1 min before administration of fentanyl 150 microg
Trial: 19034284
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy for colorectal cancer
Trial: 13129460
Drug: Coconut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut flour (200-250 g/kg) in macaroons
Trial: 13129460
Drug: Coconut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut flour (200-250 g/kg) in carrot cake
Trial: 13129460
Drug: Coconut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut flour (150 g/kg) in test foods
Trial: 13129460
Drug: Coconut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut flour (50 g/kg) in pan de sal
Trial: 13129460
Drug: Coconut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut flour (100 g/kg) in multigrain loaf
Trial: 13129460
Drug: Coconut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut flour (50 g/kg) in granola bar
Trial: 13129460
Drug: Coconut flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut flour (100 g/kg) in cinnamon bread
Trial: 6100497
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate regime (three cycles of etoposide, adriamycin and methotrexate at conventional dosage)
Trial: 6100497
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methotrexate regime (three cycles of etoposide and adriamycin with five courses of high dose methotrexate and folinic acid rescue)
Trial: 6100497
Drug: Alternative four
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative four drug regime (procarbazine, vincristine, cyclophosphamide and CCNU)
Trial: 31161374
Drug: Supportive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive and symptomatic treatments (group B)
Trial: 22274684
Drug: Lansoprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (15 mg/d if <30 kg; 30 mg/d if ≥30 kg)
Trial: 12228773
Drug: Carvedilol administered
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol administered twice daily for 8 months
Trial: 322671
Drug: Chlordesmethyldiazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordesmethyldiazepam (2 mg orally) administered for 7 consecutive evenings
Trial: 21688560
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitors (AIN's)
Trial: 9119980
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone 1000 mg daily for 3 days
Trial: 9119980
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone 48 mg daily for one week, 24 mg daily for one week, and 12 mg daily for one week
Trial: 9119980
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone regimen
Trial: 8222034
Drug: Sitting position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting position with 2.0 ml hyperbaric bupivacaine 0.5%
Trial: 8222034
Drug: Left lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left lateral position with 2.0 ml hyperbaric bupivacaine 0.5%
Trial: 3531044
Drug: Dapsone (DDS)
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone (DDS) approximately 2 mg per kilogram body weight per day for 21 days
Trial: 3531044
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving the drug)
Trial: 25490803
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of self-leveling carousel and adjustable cart
Trial: 12047603
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg triazolam (TL)
Trial: 12047603
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg triazolam (TH)
Trial: 12047603
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg brotizolam (BR)
Trial: 2265259
Drug: Adjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant tamoxifen (TM), 30 mg per day for 2 years
Trial: 31426760
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) with doses of 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, completed within 2 weeks.
Trial: 31426760
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care palliative-intent treatments (Control group).
Trial: 25862428
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of polyethylene glycol plus bisacodyl (n = 31)
Trial: 24219197
Drug: Low-intensity nonprogressive
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity nonprogressive resistance training (L-RT)
Trial: 17276533
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) to the left breast
Trial: 8975918
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide vaccine (PS) (25 micrograms of polysaccharide per serotype)
Trial: 7932517
Drug: Pravastatin 10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10-40 mg once daily
Trial: 25422235
Drug: Chongcao Yigan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chongcao Yigan Capsule
Trial: 19884368
Drug: Nemonoxacin 25
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 25 mg
Trial: 19884368
Drug: Nemonoxacin 50
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 50 mg
Trial: 19884368
Drug: Nemonoxacin 1000
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 1000 mg
Trial: 19884368
Drug: Nemonoxacin 1500
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 1500 mg